Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v2.4.0.6
Consolidated Statements of Operations and Comprehensive Loss (USD $)
3 Months Ended
Mar. 31, 2012
Mar. 31, 2011
Grant revenue $ 11,931 $ 335,962
Operating expenses:    
Research and development 3,943,714 2,435,598
Selling, general and administrative 2,574,630 2,901,707
Total operating expenses 6,518,344 5,337,305
Loss from operations (6,506,413) (5,001,343)
Other income (expense):    
Interest income 9,733 3,519
Interest expense (293,671) (1,607)
Change in derivative liabilities (184,084) (953,789)
Other (14,637) (713)
Total other expense, net (482,659) (952,590)
Loss before income taxes (6,989,072) (5,953,933)
Benefit from income tax   520,813
Loss from continuing operations (6,989,072) (5,433,120)
Discontinued operations-income from operations, net of tax effect   1,010,991
Net loss and comprehensive loss (6,989,072) (4,422,129)
Preferred stock dividends (25,000) (25,000)
Net loss and comprehensive loss attributable to common stockholders $ (7,014,072) $ (4,447,129)
Loss per common share (basic and diluted):    
Continuing operations $ (0.07) $ (0.06)
Discontinued operations   $ 0.01
Attributable to common stockholders $ (0.07) $ (0.05)
Weighted average shares outstanding:    
Basic and diluted 94,074,918 85,416,015